Goletti Delia, Petrone Linda, Manissero Davide, Bertoletti Antonio, Rao Sonia, Ndunda Nduku, Sette Alessandro, Nikolayevskyy Vladyslav
Translational Research Unit, National Institute for Infectious Diseases (INMI), "Lazzaro Spallanzani"-IRCCS, Rome, Italy.
Translational Research Unit, National Institute for Infectious Diseases (INMI), "Lazzaro Spallanzani"-IRCCS, Rome, Italy.
Clin Microbiol Infect. 2021 Dec;27(12):1784-1789. doi: 10.1016/j.cmi.2021.07.005. Epub 2021 Jul 10.
Both humoral and cell-mediated responses are associated with immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although our understanding of the potential role of T-cell responses in the context of coronavirus disease 2019 (COVID-19) is rapidly increasing, more information is still needed.
To provide an overview of the role of T-cell immunity in COVID-19, in the context of natural infection and post-vaccination, and discuss the potential utility of measuring SARS-CoV-2-specific T-cell responses, drawing on experience of the use of interferon-γ release assays (IGRAs) in tuberculosis (TB).
PubMed articles up to 16 April 2021.
T-cell responses can be detected very early in the course of COVID-19, earlier than the detection of antibody responses, and are correlated with COVID-19 outcome. Lower CD4 and CD8 T-cell counts are markers of more severe disease, longer duration of viral RNA positivity and increased mortality. In line with natural infection, SARS-CoV-2 vaccination stimulates robust T-cell responses, which probably play an important role in protection; data on long-term T-cell responses are currently limited. The utility of measuring T-cell responses is already well established in both aiding the diagnosis of TB infection using IGRAs, and evaluation of T-cell responses to TB vaccine candidates. A variety of assays have already been developed to measure SARS-CoV-2-specific T-cell responses, including IGRAs, intracellular cytokine staining and activation-induced markers. IGRAs based on SARS-CoV-2 antigens can distinguish between convalescent and uninfected healthy blood donors.
Simple assays for measuring the quantity and function of T-cell responses may have utility in the prognostication of COVID-19, and for monitoring immune responses to SARS-CoV-2 vaccination and population-based immunity to SARS-CoV-2 variants of interest.
体液免疫和细胞介导的免疫反应均与针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的免疫相关。尽管我们对T细胞反应在2019冠状病毒病(COVID-19)中的潜在作用的理解正在迅速增加,但仍需要更多信息。
概述T细胞免疫在自然感染和接种疫苗情况下对COVID-19的作用,并借鉴在结核病(TB)中使用干扰素-γ释放试验(IGRAs)的经验,讨论检测SARS-CoV-2特异性T细胞反应的潜在用途。
截至2021年4月16日的PubMed文章。
在COVID-19病程中可很早就检测到T细胞反应,早于抗体反应的检测,且与COVID-19的预后相关。较低的CD4和CD8 T细胞计数是疾病更严重、病毒RNA阳性持续时间更长和死亡率增加的标志。与自然感染一致,SARS-CoV-2疫苗接种可刺激强烈的T细胞反应,这可能在保护中起重要作用;目前关于长期T细胞反应的数据有限。测量T细胞反应的用途在辅助使用IGRAs诊断TB感染以及评估T细胞对TB候选疫苗的反应方面已得到充分证实。已经开发了多种检测方法来测量SARS-CoV-2特异性T细胞反应,包括IGRAs、细胞内细胞因子染色和激活诱导标志物。基于SARS-CoV-2抗原的IGRAs可区分康复期和未感染的健康献血者。
用于测量T细胞反应数量和功能的简单检测方法可能有助于COVID-19的预后评估,以及监测对SARS-CoV-2疫苗接种的免疫反应和人群对感兴趣的SARS-CoV-2变异株的免疫力。